-
The Medical Journal of Australia Jan 1990
Topics: Cornea; Corneal Diseases; Corneal Transplantation; Humans; Mustard Compounds; Mustard Gas
PubMed: 2294383
DOI: 10.5694/j.1326-5377.1990.tb124450.x -
Annals of the New York Academy of... Apr 1958
Topics: Mechlorethamine; Nitrogen Mustard Compounds
PubMed: 13627761
DOI: 10.1111/j.1749-6632.1958.tb42670.x -
Journal of the American Medical... Jan 1958
Topics: Chlorambucil; Mechlorethamine; Nitrogen Mustard Compounds
PubMed: 13491311
DOI: No ID Found -
The Journal of the Egyptian Medical... 1952
Topics: Mechlorethamine; Neoplasms; Nitrogen Mustard Compounds
PubMed: 13035830
DOI: No ID Found -
The Journal of Pharmacy and Pharmacology Dec 1950
Topics: Mechlorethamine; Nitrogen Mustard Compounds
PubMed: 14804313
DOI: 10.1111/j.2042-7158.1950.tb13010.x -
Canadian Journal of Research. Section... Aug 1950
Topics: Gases; Humans; Hypersensitivity; Mechlorethamine; Mustard Gas; Nitrogen Mustard Compounds
PubMed: 24537824
DOI: 10.1139/cjr50e-024 -
Seminars in Hematology Apr 2011Although the alkylating agent bendamustine was developed in Germany in the mid-twentieth century, it has only recently come to the forefront in the rest of the world as... (Review)
Review
Although the alkylating agent bendamustine was developed in Germany in the mid-twentieth century, it has only recently come to the forefront in the rest of the world as an effective chemotherapeutic agent for the treatment of several hematologic malignancies. Based on the activity demonstrated in single-arm and randomized trials, this nitrogen mustard is approved by the US Food and Drug Administration (FDA) for the treatment of chronic lymphocytic leukemia and rituximab-refractory indolent non-Hodgkin lymphoma. The unique structural and mechanistic features of bendamustine differentiate it from other alkylating agents, providing increased stability and potency in DNA cross linking and subsequent cytotoxicity. Due to its unusual development, few studies have closely examined the mechanisms of action for this nitrogen mustard and many unanswered questions remain. Additionally, phase I and pharmacokinetic studies are limited, although increased understanding of the clinical pharmacology of bendamustine led to development of dosing recommendations by international experts based on the available data. The clinical activity of bendamustine as a single agent and in combination with other chemotherapeutic and immunotherapeutic drugs, coupled with its potential lack of cross-resistance with many other chemotherapy agents, make bendamustine an attractive therapy for patients with newly diagnosed and refractory hematologic malignancies. This review will discuss the development of bendamustine, its structural and pharmacologic characteristics, and current data regarding the optimal dosing of this agent in specific clinical settings.
Topics: Animals; Antineoplastic Agents; Bendamustine Hydrochloride; Hematologic Neoplasms; Humans; Nitrogen Mustard Compounds
PubMed: 21530771
DOI: 10.1053/j.seminhematol.2011.03.002 -
Nature Dec 1950
Topics: Mechlorethamine; Mustard Compounds; Mustard Gas; Nitrogen Mustard Compounds
PubMed: 14796676
DOI: 10.1038/1661019a0 -
European Journal of Medicinal Chemistry Apr 2014A series of new, water-soluble phenyl N-mustard-benzenealkylamide conjugates containing hydrophilic ω-dialkylaminoalkylamide or ω-cyclic aminoalkylamide moieties were...
A series of new, water-soluble phenyl N-mustard-benzenealkylamide conjugates containing hydrophilic ω-dialkylaminoalkylamide or ω-cyclic aminoalkylamide moieties were synthesized via a bioisostere approach. These compounds have a broad spectrum of antitumor activity against a panel of human tumor cell lines. Of these derivatives, compound 18b effectively suppressed the growth of colon cancer (HCT-116), prostate cancer (PC3), and lung cancer (H460) xenografts. The growth of HCT-116 xenografts was almost completely suppressed when co-treated with compound 18b and 5-fluorouracil. Furthermore, compound 18b can induce DNA cross-linking and cell-cycle arrest at the G2/M phase. Early preclinical studies, including pharmacokinetics in rats, inhibition of the hERG, and 14 days of acute intravenous injection toxicity, suggest that compound 18b is a promising candidate for further preclinical studies.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Drug Screening Assays, Antitumor; Humans; In Situ Nick-End Labeling; Magnetic Resonance Spectroscopy; Male; Mice; Mice, Nude; Mustard Compounds; Rats; Spectrometry, Mass, Electrospray Ionization
PubMed: 24583355
DOI: 10.1016/j.ejmech.2014.02.018 -
The Journal of Burn Care &... 1996This is a case study of a woman who sustained a second-degree, partial-thickness burn of the midchest and medial breast distribution after the application of a heated... (Review)
Review
This is a case study of a woman who sustained a second-degree, partial-thickness burn of the midchest and medial breast distribution after the application of a heated mustard compress as a naturopathic remedy for a recent bout of pneumonia. This case study demonstrates the potential for hyperpigmentation and hypertrophic scarring associated with heated mustard burns. A photograph of the presenting burn with the region of hyperpigmentation 3 days after the injury is provided.
Topics: Administration, Topical; Burns; Chronic Disease; Female; Hot Temperature; Humans; Hyperpigmentation; Middle Aged; Mustard Compounds; Pneumonia
PubMed: 8844357
DOI: 10.1097/00004630-199607000-00012